Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced a conference call to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with non-alcoholic steatohepatitis (NASH).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced a conference call to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with non-alcoholic steatohepatitis (NASH). The call is scheduled for June 14, 2021, at 8:30 a.m. ET, with a live webcast available. Terns focuses on developing small-molecule therapies targeting NASH and chronic liver diseases, aiming to offer significant clinical benefits based on validated mechanisms of action. The details of the webcast and conference call are provided for interested stakeholders.
Positive
- Terns is hosting a call to discuss new data from the Phase 2a LIFT study for TERN-101.
- The Phase 2a LIFT study aims to address treatment for NASH, a significant chronic liver disease.
- Focus on clinically validated mechanisms of action may enhance the potential for effective therapies.
Negative
- None.
Details
News Market Reaction – TERN
The recorded move for TERN in the trading session of this news was -12.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced that the Company will host a conference call and live webcast on Monday, June 14, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with NASH. Webcast and conference call details are as follows:
Webcast link: https://edge.media-server.com/mmc/p/2gsxxmta
Live Conference Call
Domestic Callers (U.S./Canada toll-free): (833) 665-0612
International Callers: (929) 517-0403
Conference ID: 7587739
Following the live audio webcast, a replay will be available on the investors page of the Terns Pharmaceuticals website at http://ir.ternspharma.com for 30 days.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit www.ternspharma.com.
Contacts for Terns:
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.